This 1-yr extension of a previous 2-yr clinical trial investigated myopia control efficacy of highly aspherical lenslet (HAL) spectacle lenses for children wearing them for a further year and for children switching to HAL after wearing slightly aspherical lenslet (SAL) or single vision lenses. HAL design lenses were able to provide or maintain a myopia slowing effect for all wearers.
The LAMP2 study explored the efficacy of low-concentration atropine to delay the onset of myopia in at-risk children. The results found there was no significant difference between 0.01% atropine and the placebo, but 0.05% atropine was able to reduce myopia incidence and speed of myopic progression for pre-myopes.
A mixed-race cohort of Australian children demonstrated that atropine 0.01% was safe and well tolerated, although myopia control effects were only found in those of European or other/mixed ancestry. Those of East Asian or South Asian ethnicity showed no benefit. Overall results were impacted by high drop-out in the control group in the second year of the study.
We asked some key atropine questions of myopia thought leader Professor Mark Bullimore, who has published numerous landmark papers in the field, including his newest on the inconsistencies found in compounded atropine. Learn about the present and the future of atropine treatment for childhood myopia.
We had the privilege of chatting with Professor Karla Zadnik who is Principal Investigator of the CHAMP study on low-concentration atropine. Learn about how this study is a unique and important addition to our understanding of topical atropine in myopia control.
This reanalysis of data from 2 clinical trials evaluated the relative risk of fast axial eye growth in children wearing ortho-k lenses. The results showed that although younger children (6-8 years) experienced faster eye growth than older children (9-12 years), they also benefitted more from ortho-k in slowing their progression when worn for a 2-year period.
The HOYA MiYOSMART was the first of the new generation of myopia control spectacle lenses, with evidence for slowing myopia progression by at least half. Learn more about efficacy, the lens design, visual outcomes and more.
This prospective observational study found that DIMS spectacle lenses, atropine 0.01% and the combination of the two all showed robust efficacy for myopia control in European children. The combination treatment showed slightly better refractive control than the mono-therapies, but axial length growth was similar in all treatment groups.
The MiSight 1 day clinical trial is the longest-running soft contact lens study among children, and is now reporting seven-year data. With questions explored including efficacy, cross over from control group to treatment and discontinuation, here’s some of what we’ve learnt along the way.
The first year data from the ongoing CYPRESS randomized clinical trial show that Diffusion Optics Technology (DOT) spectacle lenses can regulate contrast signals across the retina to reduce myopia progression in children aged 6-10 years, and are safe and effective to wear.
